Metabolic measures 12 months after a randomised controlled trial of treatment of clozapine associated obesity and diabetes with exenatide (CODEX).

Siskind D, Russell A, Russell A, Gamble C, Baker A, Cosgrove P, Burton L, Kisely S

Journal of psychiatric research18 Feb 2020Cited by 18 (Europe PMC)

PMID32087425DOI10.1016/j.jpsychires.2020.02.015PepBankPUB-32087425

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyOther
After CODEX ended, former exenatide participants had greater weight increases than former usual care participants.
In plain wordsAfter treatment ended, weight increased more in former exenatide participants than former usual care participants.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseWeight from endpoint to follow-up
Study
n: not reported in source
Comparator
Former usual care participants
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
From endpoint to 12-month follow up there were significantly greater increases among the former exenatide versus former usual care participants for weight, BMI, HbA1c and proportion with >5% weight gain.
2 context sentences(design, population, supporting numbers)
Summary · context
Our 24-week randomized, controlled, open-label, pilot trial of once-weekly extended-release subcutaneous exenatide or usual care (CODEX) (n = 28), found exenatide was associated with significantly greater weight loss.
Summary · context
We followed up CODEX trial participants at 12-months post trial endpoint, collecting information on weight, BMI, waist circumference, blood pressure, fasting glucose, HbA1c, and use of metformin.
Report a problemFND-3208742502
02HumanObservational studyOther
In former CODEX participants, HbA1c differed between former exenatide and control groups from baseline to follow-up.
In plain wordsAt follow-up, HbA1c differed between former exenatide and control groups relative to baseline.
Peptide
Exenatide (exendin-4)
Outcome
Direction not reportedHbA1c from baseline to follow-up
Study
n: not reported in source
Comparator
Former usual care participants
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
Only HbA1c differed between baseline and 12-months post endpoint between the exenatide and control groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Our 24-week randomized, controlled, open-label, pilot trial of once-weekly extended-release subcutaneous exenatide or usual care (CODEX) (n = 28), found exenatide was associated with significantly greater weight loss.
Summary · context
We followed up CODEX trial participants at 12-months post trial endpoint, collecting information on weight, BMI, waist circumference, blood pressure, fasting glucose, HbA1c, and use of metformin.
Report a problemFND-3208742501
03HumanObservational studyOther
After CODEX ended, former exenatide participants had greater BMI increases than former usual care participants.
In plain wordsAfter treatment ended, BMI increased more in former exenatide participants than former usual care participants.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBMI from endpoint to follow-up
Study
n: not reported in source
Comparator
Former usual care participants
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
From endpoint to 12-month follow up there were significantly greater increases among the former exenatide versus former usual care participants for weight, BMI, HbA1c and proportion with >5% weight gain.
2 context sentences(design, population, supporting numbers)
Summary · context
Our 24-week randomized, controlled, open-label, pilot trial of once-weekly extended-release subcutaneous exenatide or usual care (CODEX) (n = 28), found exenatide was associated with significantly greater weight loss.
Summary · context
We followed up CODEX trial participants at 12-months post trial endpoint, collecting information on weight, BMI, waist circumference, blood pressure, fasting glucose, HbA1c, and use of metformin.
Report a problemFND-3208742503
04HumanObservational studyOther
After CODEX ended, former exenatide participants had greater HbA1c increases than former usual care participants.
In plain wordsAfter treatment ended, HbA1c increased more in former exenatide participants than former usual care participants.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseHbA1c from endpoint to follow-up
Study
n: not reported in source
Comparator
Former usual care participants
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
From endpoint to 12-month follow up there were significantly greater increases among the former exenatide versus former usual care participants for weight, BMI, HbA1c and proportion with >5% weight gain.
2 context sentences(design, population, supporting numbers)
Summary · context
Our 24-week randomized, controlled, open-label, pilot trial of once-weekly extended-release subcutaneous exenatide or usual care (CODEX) (n = 28), found exenatide was associated with significantly greater weight loss.
Summary · context
We followed up CODEX trial participants at 12-months post trial endpoint, collecting information on weight, BMI, waist circumference, blood pressure, fasting glucose, HbA1c, and use of metformin.
Report a problemFND-3208742504
05HumanObservational studyOther
After CODEX ended, the proportion with >5% weight gain was higher among former exenatide than former usual care participants.
In plain wordsAfter treatment ended, >5% weight gain was more common in former exenatide participants than former usual care participants.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseProportion with greater than 5% weight gain
Study
n: not reported in source
Comparator
Former usual care participants
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
From endpoint to 12-month follow up there were significantly greater increases among the former exenatide versus former usual care participants for weight, BMI, HbA1c and proportion with >5% weight gain.
2 context sentences(design, population, supporting numbers)
Summary · context
Our 24-week randomized, controlled, open-label, pilot trial of once-weekly extended-release subcutaneous exenatide or usual care (CODEX) (n = 28), found exenatide was associated with significantly greater weight loss.
Summary · context
We followed up CODEX trial participants at 12-months post trial endpoint, collecting information on weight, BMI, waist circumference, blood pressure, fasting glucose, HbA1c, and use of metformin.
Report a problemFND-3208742505

Studies that did not test the peptide alone5

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

06HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In CODEX follow-up, weight did not differ significantly between baseline and follow-up.
In plain wordsAt CODEX follow-up, weight did not differ significantly from baseline.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeWeight from baseline to follow-up
Study
n: not reported in source
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Although there were no significant differences in weight and BMI between baseline and 12-month post endpoint, there were significant increases in weight and BMI in the 12 months post endpoint for the former exenatide group.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined whether this effect was maintained at 12-months post-intervention.
Summary · context
We followed up CODEX trial participants at 12-months post trial endpoint, collecting information on weight, BMI, waist circumference, blood pressure, fasting glucose, HbA1c, and use of metformin.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3208742507
07HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In CODEX follow-up, stratification by metformin use did not alter the proportion with >5% weight gain.
In plain wordsAt follow-up, grouping participants by metformin use did not change the proportion with >5% weight gain.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeWeight gain proportion stratified by metformin use
Study
n: not reported in source
Comparator
Stratification by post-trial metformin use
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Stratifying results by whether participants used metformin post trial did not alter proportion with >5% weight gain.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined whether this effect was maintained at 12-months post-intervention.
Summary · context
We followed up CODEX trial participants at 12-months post trial endpoint, collecting information on weight, BMI, waist circumference, blood pressure, fasting glucose, HbA1c, and use of metformin.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3208742506
08HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In CODEX follow-up, BMI did not differ significantly between baseline and follow-up.
In plain wordsAt CODEX follow-up, BMI did not differ significantly from baseline.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeBMI from baseline to follow-up
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Although there were no significant differences in weight and BMI between baseline and 12-month post endpoint, there were significant increases in weight and BMI in the 12 months post endpoint for the former exenatide group.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined whether this effect was maintained at 12-months post-intervention.
Summary · context
We followed up CODEX trial participants at 12-months post trial endpoint, collecting information on weight, BMI, waist circumference, blood pressure, fasting glucose, HbA1c, and use of metformin.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3208742508
09HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In former exenatide participants, weight increased significantly after the CODEX endpoint.
In plain wordsIn former exenatide participants, weight increased significantly after treatment ended.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseWeight within former exenatide group
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Although there were no significant differences in weight and BMI between baseline and 12-month post endpoint, there were significant increases in weight and BMI in the 12 months post endpoint for the former exenatide group.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined whether this effect was maintained at 12-months post-intervention.
Summary · context
We followed up CODEX trial participants at 12-months post trial endpoint, collecting information on weight, BMI, waist circumference, blood pressure, fasting glucose, HbA1c, and use of metformin.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3208742509
10HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In former exenatide participants, BMI increased significantly after the CODEX endpoint.
In plain wordsIn former exenatide participants, BMI increased significantly after treatment ended.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseBMI within former exenatide group
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
Although there were no significant differences in weight and BMI between baseline and 12-month post endpoint, there were significant increases in weight and BMI in the 12 months post endpoint for the former exenatide group.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined whether this effect was maintained at 12-months post-intervention.
Summary · context
We followed up CODEX trial participants at 12-months post trial endpoint, collecting information on weight, BMI, waist circumference, blood pressure, fasting glucose, HbA1c, and use of metformin.
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-3208742510

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.